The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.
Fiche publication
Date publication
avril 2014
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Delvincourt M, Lopez A, Pillet S, Bourrier A, Seksik P, Cosnes J, Carrat F, Gozlan J, Beaugerie L, Roblin X, Peyrin-Biroulet L, Sokol H
Lien Pubmed
Résumé
Consequences of latent cytomegalovirus (CMV) infection reactivation on inflammatory bowel disease (IBD) flare, as a flare-worsening factor or simple bystander, are debated. Impact of anti-viral treatment on IBD course is poorly known.
Mots clés
Adult, Antiviral Agents, therapeutic use, Case-Control Studies, Colitis, Ulcerative, diagnosis, Cytomegalovirus, genetics, Cytomegalovirus Infections, diagnosis, DNA, Viral, analysis, Female, France, epidemiology, Humans, Immunosuppressive Agents, therapeutic use, Male, Middle Aged, Polymerase Chain Reaction, Virus Activation, Young Adult
Référence
Aliment. Pharmacol. Ther.. 2014 Apr;39(7):712-20